2 recruiting, 1 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Christine Ryan: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation Glofitamab, Obinutuzumab, Polatuzumab Vedotin - Chronic Lymphocytic Leukemia, Richter's Transformation | Phase 2 | Recruiting | Christine Ryan | 70 | 2024-01-22 | 2026-10-21 |
| Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma Rituximab, Bendamustine, Cytarabine - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Christine Ryan | 23 | 2012-08-16 | 2026-06-08 |
Lymphoma, Mantle-Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1)
Bendamustine Hydrochloride (2) · Cytarabine (2) · Rituximab (2) · atezolizumab (1) · glofitamab (1) · obinutuzumab (1) · pirtobrutinib (1) · polatuzumab vedotin (1) · tocilizumab (1) · zanubrutinib (1)
United States (3)